Phase III trial of single dose Sputnik Light vaccine approved in the country, know how different it is from Sputnik-V
The fight against Corona in the country has intensified. The Drugs Controller General of India (DCGI) has given permission for the Phase III trial of Russia's Sputnik Light Vaccine in India. It is known that this is a single dose vaccine, after which another dose will not be needed. All the vaccines being administered in India now require two doses.
This approval has been given after a recent study published in the medical journal 'The Lancet'. It has been found in this study that Sputnik Light has shown an efficacy of 78.6 to 83.7 percent against Kovid-19. This is much higher than most two-dose vaccines. In July this year, the subject expert committee of the Central Drugs Standard Control Organization (CDSCO) refused to approve the emergency use of Sputnik-Lite.
After this, the Drugs Regulator (DCGI) also refused to approve the emergency use of Sputnik Light. Not only this, the need for the third phase trial of this vaccine in the country was also rejected. At that time the expert committee had said that the components of Sputnik Light are also similar to Sputnik-V. Now with the approval of the trial of Sputnik Light Vaccine, the way has been cleared for getting another weapon against Corona.
Meanwhile, the Russian Direct Investment Fund (RDIF) has said that the two-dose Russian Sputnik-V vaccine has shown 97.2 percent efficacy against corona in Belarus. The effectiveness of Sputnik-V was measured based on data from more than 860,000 people who were vaccinated between January and July 2021, according to a statement issued by news agency ANI. The health ministry's data also confirms the high security of Sputnik-V, the statement said.